WO2015013233A3 - Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie - Google Patents

Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie Download PDF

Info

Publication number
WO2015013233A3
WO2015013233A3 PCT/US2014/047535 US2014047535W WO2015013233A3 WO 2015013233 A3 WO2015013233 A3 WO 2015013233A3 US 2014047535 W US2014047535 W US 2014047535W WO 2015013233 A3 WO2015013233 A3 WO 2015013233A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
bladder cancer
diagnosis
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/047535
Other languages
English (en)
Other versions
WO2015013233A2 (fr
Inventor
Karen Chapman
Joseph Wagner
Michael West
Jennifer Lorrie KIDD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Molecular Diagnostics Inc
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of WO2015013233A2 publication Critical patent/WO2015013233A2/fr
Publication of WO2015013233A3 publication Critical patent/WO2015013233A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés, des compositions et des trousses pour la détection et le traitement du cancer de la vessie.
PCT/US2014/047535 2013-07-23 2014-07-22 Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie Ceased WO2015013233A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857333P 2013-07-23 2013-07-23
US61/857,333 2013-07-23

Publications (2)

Publication Number Publication Date
WO2015013233A2 WO2015013233A2 (fr) 2015-01-29
WO2015013233A3 true WO2015013233A3 (fr) 2015-11-12

Family

ID=52393951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/047535 Ceased WO2015013233A2 (fr) 2013-07-23 2014-07-22 Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie

Country Status (1)

Country Link
WO (1) WO2015013233A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214189A1 (fr) * 2016-06-06 2017-12-14 Oncocyte Corporation Méthodes et compositions pour la détection et le diagnostic du cancer de la vessie
ES2921701T3 (es) 2016-08-05 2022-08-30 Univ New York State Res Found Queratina 17 como un biomarcador para el cáncer de vejiga
EP3336547A1 (fr) * 2016-12-13 2018-06-20 Lionex GmbH Nouveaux marqueurs biologiques du cancer de la vessie humaine et leur utilisation en diagnostic

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086932A1 (en) * 2007-03-20 2010-04-08 Indas Biotech, S.L.U. Bladder cancer diagnosis and/or prognosis method
US20100131432A1 (en) * 2008-11-17 2010-05-27 Kennedy Giulia C Methods and compositions of molecular profiling for disease diagnostics
US20120083424A1 (en) * 2002-11-01 2012-04-05 Lars Dyrskjot Andersen Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression
US20130183345A1 (en) * 2003-11-03 2013-07-18 Catalyst Assets, Llc Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083424A1 (en) * 2002-11-01 2012-04-05 Lars Dyrskjot Andersen Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression
US20130183345A1 (en) * 2003-11-03 2013-07-18 Catalyst Assets, Llc Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers
US20100086932A1 (en) * 2007-03-20 2010-04-08 Indas Biotech, S.L.U. Bladder cancer diagnosis and/or prognosis method
US20100131432A1 (en) * 2008-11-17 2010-05-27 Kennedy Giulia C Methods and compositions of molecular profiling for disease diagnostics

Also Published As

Publication number Publication date
WO2015013233A2 (fr) 2015-01-29

Similar Documents

Publication Publication Date Title
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
WO2014116833A3 (fr) Compositions et procédés de détection de néoplasie
IL252796A0 (en) Therapeutic, diagnostic and prognostic methods for bladder cancer
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2015153513A8 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
WO2015066452A3 (fr) Méthodes de traitement de cancers pédiatriques
EP3258966A4 (fr) Méthodes, compositions et trousses pour le traitement du cancer
WO2015164392A3 (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
EP3320116A4 (fr) Procédés permettant de diagnostiquer un cancer de la vessie
EP2996721A4 (fr) Méthodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8
WO2014197835A3 (fr) Méthodes et compositions pour le traitement du cancer
WO2014071067A3 (fr) Traitement et diagnostic du cancer du côlon
WO2015179835A3 (fr) Biomarqueurs mit et leurs méthodes d'utilisation
WO2016094374A8 (fr) Compositions et méthodes de traitement de l'ataxie de friedreich
EP3642233A4 (fr) Immunosignatures pour diagnostic différentiel
WO2015187727A3 (fr) Mammographie moléculaire
WO2017103280A9 (fr) Traitement intravésical du cancer de la vessie
WO2017181163A3 (fr) Méthodes et compositions pour la détection et le diagnostic du cancer du sein
WO2013052108A3 (fr) Méthodes et compositions destinées à traiter et à diagnostiquer un cancer de l'ovaire
WO2017187343A3 (fr) Nanoémulsions et méthodes pour la cancérothérapie
EP3089745A4 (fr) Composés, compositions et méthodes de traitement de cancers
WO2015013233A3 (fr) Procédés et compositions pour le traitement et le diagnostic du cancer de la vessie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14829279

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14829279

Country of ref document: EP

Kind code of ref document: A2